லூயிஜி கோஸ்டா News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from லூயிஜி கோஸ்டா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In லூயிஜி கோஸ்டா Today - Breaking & Trending Today
Facts Article 1(7) of Decree-Law 105/2010, as amended by Law 129/2010, provided that the tariffs granted to incentivise the development of solar PV plants pursuant to a ministerial decree of 19 February 2007 (known as the Secondo Conto Energia ) would be awarded to applicants that, among other things: completed construction of the plant by 31 December 2010; and notified the authority that authorised the construction, the grid operator and GSE SpA of such completion. On 23 November 2018 GSE SpA issued an order revoking the Secondo Conto Energia incentives awarded to a company operating a solar PV plant located in the municipality of Pavia, alleging that the company had failed to communicate to the authorising authority (ie, the province) that the plant s construction had been completed by 31 December 2010. ....
Norton Rose Fulbright advises Enel on a partnership with QIA to develop renewables in Sub-Saharan Africa Search Polity Note: Search is limited to the most recent 250 articles. To access earlier articles, click Advanced Search and set an earlier date range. To search for a term containing the & symbol, click Advanced Search and use the search headings and/or in first paragraph options. With. Clear Search Sponsored by Sponsored by Global law firm Norton Rose Fulbright has advised Enel’s renewable arm Enel Green Power (EGP) on a joint venture partnership with the sovereign wealth fund of the State of Qatar, Qatar Investment Authority (QIA). The joint venture will finance, build and operate renewable projects in Sub-Saharan Africa. ....
Noema Pharma AG, a Basel, Switzerland-based clinical-stage company targeting orphan neurological disorders, raised a Series A financing round, raising CHF54m ($59m USD). The round was co-led by Sofinnova Partners and Polaris Partners with participation from new international investors Gilde Healthcare, Invus and BioMed Partners. Roche, the Swiss multinational healthcare company, received a shareholding in Noema in exchange for rights to four clinical-stage product-candidates. In conjunction with the funding, Darren Carroll of Polaris Partners and Arthur Franken of Gilde Healthcare joined Antoine Papiernik of Sofinnova Partners on the Board of Directors. The company intends to use the funds to further develop its clinical-stage pipeline. The product candidates will be developed in neurological indications with severe unmet need, such as seizures in tuberous sclerosis complex (TSC), trigeminal neuralgia, Tourette syndrome and other rare neurological disorders. ....